EUropean QUalification Approach for Low EnrIched Fuel sYstems for secure product...
EUropean QUalification Approach for Low EnrIched Fuel sYstems for secure production supply of medical isotopes
One of the biggest challenges for European research reactors is securing their nuclear fuel supply to ensure a sustainment of medical isotopes for Europe and the world. This is particularly true for the few operating High Performa...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto EU-QUALIFY
Duración del proyecto: 47 meses
Fecha Inicio: 2020-10-01
Fecha Fin: 2024-09-30
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
One of the biggest challenges for European research reactors is securing their nuclear fuel supply to ensure a sustainment of medical isotopes for Europe and the world. This is particularly true for the few operating High Performance Research Reactors (HPRRs) in Europe, which produce the vast majority of medical isotopes. The obligation to convert them from high to low enriched uranium (LEU) nuclear fuels while keeping similar radioisotopes production ratios makes it necessary to develop higher uranium density fuels. The R&D related to that topic was started in previous EURATOM projects (HERACLES-CP and LEU-FOREvER). The main goal of the EU-QUALIFY project is to qualify such fuels and qualify the capability to fabricate such fuels. This will be done by a multi-disciplinary consortium composed of fuel designers/manufactures, reactor operators, research organizations and a university, namely: SCK CEN, CEA, CERCA, ILL, TUM, and G-INP.The EU-QUALIFY project will build on previous LEU fuel development work with specific focus on the qualification of three particular types of fuels: the dispersed U-Mo, the monolithic U-Mo and the high-loaded dispersed U3Si2 fuels. This qualification will be accomplished through fabrication and concurrent qualification of pilot manufacturing equipment and processes, irradiation under representative irradiation conditions, post-irradiation examinations, as well as modelling of the in-pile behavior to support LEU conversion safety analyses. This project will contribute to ensuring the availability of HPPR’s, and thus enhance the security of the EU’s capacity in the production of medical radioisotopes. It will thus contribute to health care through provision of innovative medical radioisotopes necessary for diagnostic and therapy and will support European industry by maintaining access to research reactor irradiation capabilities.